Novavax secures multicountry access to COVID-19 vaccine

Building on its commitment to make its COVID-19 vaccine globally accessible, Novavax closed two partnerships this week to supply Japan, India and lower income countries with doses of NVX-CoV2373. The biotech plans to start a Phase III trial of the vaccine in October.

Meanwhile, fellow vaccine maker VBI secured a $42 million award from the Canadian government to develop its candidate. The week also saw Gilead partner with Pfizer to manufacture remdesivir, and authorization for a pair of antibody tests from Siemens. ...